Go to Top

Osseon™ Therapeutics Announces the Commercial Release of Osseoflex™ and Osseoperm™

SANTA ROSA, CA – January 26, 2009 – Osseon Therapeutics, Inc., located in Santa Rosa, California, announced today the commercial release of their Osseoflex™ and Osseoperm™ systems for the treatment of spinal bone injuries. These products combine to form a unique, new procedure termed Osseoplasty™, which allows for a minimally invasive treatment of painful compression fractures of the spine, seen increasingly in older individuals with osteoporosis. Thousands more develop compression fractures as a result of trauma or malignant disease such as breast cancer, prostate cancer and myeloma (bone cancer).

Osseoflex is a steerable and curvable needle that can access the majority of the vertebral body from a single percutaneous access point. The Osseoperm system is customized to deliver optimal cement viscosity and precise cement placement through the Osseoflex needle. As a result, the Osseoplasty procedure provides rapid stabilization of vertebral fractures and significant pain relief in most patients within the same day. Other systems require multiple access sites, open cement preparation with staff exposure to volatile chemicals, and do not allow for access to all vertebral body sites or predictable cement placement.

"We successfully completed our limited market release this month in ten U.S. medical centers, and we're very gratified by the safety and efficacy of the Osseoplasty System for the treatment of vertebral compression fractures", said John Stalcup Ph.D., Chief Executive Officer of Osseon.

Osseon plans to market its Osseoplasty System throughout the United States, and also anticipates regulatory clearance in Europe in 2009.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.

Osseon is a registered trademark of Osseon Therapeutics, Inc.

 

CONTACT: Michael Bivens, Director of Business Development, 707.636.5953